Clinically Relevant Molecular Subtypes in Leiomyosarcoma

Share this content:

the Cancer Therapy Advisor take:

Confirmed molecular subtypes in leiomyosarcoma are linked to distinct clinical outcomes, according to an article published online in the journal Clinical Cancer Research.

The authors used three previously identified molecular subtypes in leiomyosarcoma and aimed to determine whether their presence could be confirmed in independent cohorts.

In this study, 99 cases of leiomyosarcoma were profiled using 3’end RNA-Sequencing (3SEQ), but only 82 from The Cancer Genome Atlas (TCGA) were used to identify and confirm the existence of the three molecular subtypes.

Investigators identified two new formalin-fixed, paraffin-embedded tissue-compatible diagnostic immunohistochemical markers: LMOD1 for the first subtype and ARL4C for the second subtype.

Using a leiomyosarcoma tissue microarray sample with known clinical outcome, it was determined that subtype I was associated with a positive outcome in extrauterine leiomyosarcoma and that subtype II was related to a negative outcome in both uterine and extrauterine leiomyosarcoma.

The different molecular subtypes in leiomyosarcoma showed significant variations in gene expression levels, which suggest that they may respond differentially to the novel targeted therapies being developed.

Doxorubicin-ifosfamide Combo Improves PFS in Soft Tissue Sarcoma
Confirmed molecular subtypes in leiomyosarcoma are linked to distinct clinical outcomes.
Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation. Little is known about its molecular heterogeneity and no targeted therapy currently exists for leiomyosarcoma.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs